Status:
TERMINATED
Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Cannabis Dependence
Cannabis Abuse
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
The primary purpose is to assess the efficacy in human of N-acetylcysteine versus placebo during 4 weeks in cannabis withdrawal.
Detailed Description
Introduction:There are few clinical trials on pharmacotherapies in marijuana dependence. There is no randomized and double-blind trial on N-acetylcysteine efficacy in marijuana withdrawal.Aims:The fir...
Eligibility Criteria
Inclusion
- \> 18 year old
- Not pregnant or breast feeding
- Cannabis abuse or dependence diagnosis (DSM-IV)
- Acceptance of the trial and consent signed, validated by ethic committee
- Patient affiliated to social insurance care
Exclusion
- Contraindication to N-acetylcystein : allergic to N-acetylcystein, severe allergic illness, PHENYLCETONURIA, lactose intolerance, gastro-duodenal ulcer.
- Severe somatic disease not stabilized : diabetes, epilepsia, recent myocardial infarcts, asthma.
- Severe mental disease not stabilized : schizophrenia.
Key Trial Info
Start Date :
February 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2015
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT01439828
Start Date
February 1 2012
End Date
February 1 2015
Last Update
June 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de Psychiatrie - Hôpital Lariboisière
Paris, France, 75010